Dataset Information


Driving CARs on the uneven road of antigen heterogeneity in solid tumors.

ABSTRACT: Uniform and strong expression of CD19, a cell surface antigen, on cells of B-cell lineage is unique to hematologic malignancies. Tumor-associated antigen (TAA) targets in solid tumors exhibit heterogeneity with regards to intensity and distribution, posing a challenge for chimeric antigen receptor (CAR) T-cell therapy. Novel CAR designs, such as dual TAA-targeted CARs, tandem CARs, and switchable CARs, in conjunction with inhibitory CARs, are being investigated as means to overcome antigen heterogeneity. In addition to heterogeneity in cancer-cell antigen expression, the key determinants for antitumor responses are CAR expression levels and affinity in T cells. Herein, we review CAR T-cell therapy clinical trials for patients with lung or pancreatic cancers, and provide detailed translational strategies to overcome antigen heterogeneity.


PROVIDER: S-EPMC5943172 | BioStudies | 2018-01-01


REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6448045 | BioStudies
2017-01-01 | S-EPMC5423782 | BioStudies
2013-01-01 | S-EPMC3881605 | BioStudies
2018-01-01 | S-EPMC6257951 | BioStudies
2012-01-01 | S-EPMC3319867 | BioStudies
2020-01-01 | S-EPMC7037261 | BioStudies
2014-01-01 | S-EPMC4139067 | BioStudies
2018-01-01 | S-EPMC6428197 | BioStudies
2019-01-01 | S-EPMC7477921 | BioStudies
2020-01-01 | S-EPMC7279007 | BioStudies